与肠道微生物群相互作用的食草药:作为抗中风剂的作用
Food science and biotechnology
|February 17, 2025
概括
饮食草药可以通过调节肠道微生物群来预防和治疗中风. 草药化合物被肠道微生物转化为有益的分子,为与中风相关的损伤提供治疗效果.
科学领域:
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
背景情况:
- 脑卒中是一个主要的健康问题,具有复杂的病理生理学.
- 肠道微生物群的改变越来越多地与中风发生率和结果有关.
- 饮食干预措施,特别是草药,在调节肠道健康方面表现有前途.
研究的目的:
- 审查中风和肠道微生物群之间的双向关系.
- 阐明中风中肠道微生物群介导的饮食草药干预的机制.
- 确定中风治疗和药物开发的未来研究方向.
主要方法:
- 文献综述专注于研究饮食草药,肠道微生物群和中风的研究.
- 分析涉及草药化合物的微生物代谢的机制.
- 综合当前对肠道微生物群与中风中的食草药相互作用的理解.
主要成果:
- 饮食草药调节肠道微生物群的组成和结构,影响中风的预防.
- 肠道微生物群将草本成分代谢成用于中风治疗的生物活性分子.
- 草药干预通过抑制炎症,氧化应激和亡产生治疗作用.
结论:
- 肠道微生物群介导的饮食草药干预措施代表了对中风的有希望的治疗策略.
- 了解这些相互作用对于开发新的中风治疗方法和药物至关重要.
- 需要进一步的研究才能充分探索这个领域的潜力.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
301
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
301
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
177
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
177
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
144
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
144
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
106
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
106
Factors Influencing Drug Absorption: Disease States and Pharmacology
407
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
407
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
457
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
457


